StreetInsider.com News Articles

Hemab shares sutacimig Phase 2 data at ISTH 2026 congress

Tue, 14 Jul 2026 07:45:19 -0400

Hemab Therapeutics (Nasdaq: COAG) presented clinical and preclinical data for its drug candidate sutacimig at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, according to a company statement.

Phase 2 long-term extension data covered 34 patients with Glanzmann thrombasthenia (GT) at a median of 6.9 months of exposure and up to 15.9 months. Among participants who had bled during the run-in period, 92% experienced reductions in treated bleed rates. In participants who had experienced high-intensity bleeding events — defined as those requiring transfusions, recombinant Factor VIIa, or hospitalization — the mean high-intensity annualized treated bleed event rate

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Tue, 14 Jul 2026 07:45:00 -0400

Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026

Preclinical data for sutacimig in Factor VII deficiency (FVIID) demonstrate restoration of thrombin generation under disease-mimicking conditions and support its potential as a pan-hemostatic agent

Natural history studies in Glanzmann thrombasthenia (GT) confirm lifelong bleeding burden and critical underutilization of prophylaxis, underscoring the urgent need for preventive treatment

ISTH 2026 included nine total Hemab-led presentations delivering new clinical and preclinical data across sutacimig, HMB-002, and HMB-003

CAMBRIDGE, Mass. and COPENHAGEN,

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Tue, 14 Jul 2026 07:45:00 -0400

Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026

Preclinical data for sutacimig in Factor VII deficiency (FVIID) demonstrate restoration of thrombin generation under disease-mimicking conditions and support its potential as a pan-hemostatic agent

Natural history studies in Glanzmann thrombasthenia (GT) confirm lifelong bleeding burden and critical underutilization of prophylaxis, underscoring the urgent need for preventive treatment

ISTH 2026 included nine total Hemab-led presentations delivering new clinical and preclinical data across sutacimig, HMB-002, and HMB-003

CAMBRIDGE, Mass. and COPENHAGEN,

Hemab Therapeutics Holdings (COAG) PT Raised to $47 at Jefferies

Mon, 13 Jul 2026 08:51:29 -0400

Jefferies analyst Maury Raycroft raised the price target on Hemab Therapeutics Holdings (NASDAQ: COAG) to $47.00 (from $39.00) while maintaining a Buy rating.

Hemab Therapeutics Holdings (COAG) PT Raised to $52 at H.C. Wainwright

Mon, 13 Jul 2026 06:40:35 -0400

(Updated - July 13, 2026 6:40 AM EDT)

H.C. Wainwright analyst Emily Bodnar raised the price target on Hemab Therapeutics Holdings (NASDAQ: COAG) to $52.00 (from $40.00) while maintaining a Buy rating.

The analyst commented: "Over the weekend at ISTH, Hemab presented additional HMB-002 data from the Part A SAD portion of the Phase 1/2 Velora Pioneer trial that, in our view, materially strengthens the proof-of-mechanism (PoM) case in VWD. The previously reported A1 (20 mg) and A2 (50 mg) cohorts showed dose-dependent VWF and FVIII elevations that exceeded the ~1.5x hemostatic threshold but were sustained only 8-10 days. The updated data

Hemab Therapeutics Holdings (COAG) PT Raised to $52 at H.C. Wainwright

Mon, 13 Jul 2026 06:40:35 -0400

(Updated - July 13, 2026 6:40 AM EDT)

H.C. Wainwright analyst Emily Bodnar raised the price target on Hemab Therapeutics Holdings (NASDAQ: COAG) to $52.00 (from $40.00) while maintaining a Buy rating.

Hemab shares clinical data on HMB-002, unveils HMB-003 program

Mon, 13 Jul 2026 05:44:00 -0400

Hemab Therapeutics (Nasdaq: COAG) presented clinical data from its HMB-002 program in Von Willebrand disease (VWD) and announced a new drug candidate, HMB-003, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France.

HMB-002, a monovalent human antibody administered subcutaneously, is designed to elevate the body's endogenous levels of Von Willebrand Factor (VWF) and Factor VIII (FVIII) rather than infusing exogenous factor. In its highest tested dose cohort of 150 mg, the drug produced at least a 2.4-fold increase in both VWF and FVIII, along with normalization of thrombin generation and activated partial thromboplastin time. The pharmacokinetic

Hemab shares clinical data on HMB-002, unveils HMB-003 program

Mon, 13 Jul 2026 05:44:00 -0400

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

Sun, 12 Jul 2026 06:28:00 -0400

HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin generation and activated partial thromboplastin time (APTT), and durability supporting potential monthly subcutaneous dosing

HMB-003 program announced as non-hormonal direct plasmin inhibitor with potent, selective and extended antifibrinolytic activity, designed to reduce bleeding across multiple settings beginning in heavy menstrual bleeding